Filing Details
- Accession Number:
- 0001209191-10-019877
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-04-01 13:00:00
- Reporting Period:
- 2010-03-31
- Filing Date:
- 2010-04-01
- Accepted Time:
- 2010-04-01 18:40:43
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1333248 | Cadence Pharmaceuticals Inc | CADX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1378690 | R Theodore Schroeder | C/O Cadence Pharmaceuticals, Inc. 12481 High Bluff Drive, Suite 200 San Diego CA 92130 | President, Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2010-03-31 | 28,003 | $9.30 | 432,997 | No | 4 | S | Indirect | By the Schroeder Living Trust |
Common Stock | Disposition | 2010-04-01 | 21,997 | $9.03 | 411,000 | No | 4 | S | Indirect | By the Schroeder Living Trust |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | By the Schroeder Living Trust |
No | 4 | S | Indirect | By the Schroeder Living Trust |
Footnotes
- The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 16, 2009.
- This transaction was executed in multiple trades at prices ranging from a low of $9.11 to a high of $9.52. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- Mr. Schroeder is the trustee of this trust.
- This transaction was executed in multiple trades at prices ranging from a low of $8.95 to a high of $9.13. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.